Contributions
Abstract: EP1579
Type: ePoster
Abstract Category: RIMS - Symptoms Management
Objective: People with multiple sclerosis (MS) report walking as the most important body function. Fampridine SR, a potent inhibitor of voltage gated potassium channel, improve conduction in demyelinated nerve fibers and therefore improved walking speed in MS patients. It was shown that fampridine SR also improved arm function, fatigue and quality of life. Timed 10 m walk (T10mW) primary evaluated walking speed and only to minor extend other elements of walking, coordination and balance. SSST asses not only walking speed but also coordination and balance.
The aim of our study was to compare the responsiveness of the SSST and T10mW after SR fampridine treatment.
Methods: Our prospective study included 110 patients, with different type of MS, aged 51,5±10,1 years and EDSS 5,3±1,0. They were treated with SR famprideine twice daily. The examination was performed before treatment and after 14 days. The responders were defined on 20% or greater improvement on T10mW.
Results: Response rate was 76%. More precisely, there was a significant difference between SSST before (mean=16.30, SD=6.9) and after (mean=14.80, SD=6.13) the treatment, (t(21)=3.53, p=0.002). There was also a significant difference between T10mW test before (mean=14.60, SD=10.10) and after (mean=13.12, SD=9.06) treatment, t(23)=4.05, p< 0.0001. Change on SSST differed significantly from T10mW (30,1 ± 15,1%, vs.T10mW 18,1 ± 10,1%, p=0,002). The EDSS scores correlated positively with difference between T10mW test before and after treatment r=0.430, p=0.036, meaning that as the EDSS increased the difference in treatment increased as well, probably suggesting a better efficacy of the treatment in patients with higher EDSS.
Conclusion: SR fampridine has significant effects on different domains, including coordination and balance. SSST is more responsive to the effect of SR fampridine treatment than T10mW. Our data suggest better efficacy of SR fampridine treatment in patients with higher EDSS.
Disclosure: Nothing to disclose
Abstract: EP1579
Type: ePoster
Abstract Category: RIMS - Symptoms Management
Objective: People with multiple sclerosis (MS) report walking as the most important body function. Fampridine SR, a potent inhibitor of voltage gated potassium channel, improve conduction in demyelinated nerve fibers and therefore improved walking speed in MS patients. It was shown that fampridine SR also improved arm function, fatigue and quality of life. Timed 10 m walk (T10mW) primary evaluated walking speed and only to minor extend other elements of walking, coordination and balance. SSST asses not only walking speed but also coordination and balance.
The aim of our study was to compare the responsiveness of the SSST and T10mW after SR fampridine treatment.
Methods: Our prospective study included 110 patients, with different type of MS, aged 51,5±10,1 years and EDSS 5,3±1,0. They were treated with SR famprideine twice daily. The examination was performed before treatment and after 14 days. The responders were defined on 20% or greater improvement on T10mW.
Results: Response rate was 76%. More precisely, there was a significant difference between SSST before (mean=16.30, SD=6.9) and after (mean=14.80, SD=6.13) the treatment, (t(21)=3.53, p=0.002). There was also a significant difference between T10mW test before (mean=14.60, SD=10.10) and after (mean=13.12, SD=9.06) treatment, t(23)=4.05, p< 0.0001. Change on SSST differed significantly from T10mW (30,1 ± 15,1%, vs.T10mW 18,1 ± 10,1%, p=0,002). The EDSS scores correlated positively with difference between T10mW test before and after treatment r=0.430, p=0.036, meaning that as the EDSS increased the difference in treatment increased as well, probably suggesting a better efficacy of the treatment in patients with higher EDSS.
Conclusion: SR fampridine has significant effects on different domains, including coordination and balance. SSST is more responsive to the effect of SR fampridine treatment than T10mW. Our data suggest better efficacy of SR fampridine treatment in patients with higher EDSS.
Disclosure: Nothing to disclose